Lipocine’s Oral Brexanolone Fails Phase 3 Endpoint, Shows −7.2 HAM-D Gains
In Lipocine’s Phase 3 trial of oral brexanolone LPCN 1154 (N=90), the primary endpoint—HAM-D17 score reduction at hour 60—was not met versus placebo, with no severe adverse events. In a post hoc subset (n=54 with psychiatric history), LPCN 1154 showed HAM-D17 reductions by hour 12 (−7.2, P<0.001) through day 30.
1. Phase 3 Trial Results
Lipocine enrolled 90 postpartum depression patients in a placebo-controlled Phase 3 study of oral brexanolone LPCN 1154, evaluating HAM-D17 change at hour 60. The primary endpoint was not met versus placebo, though LPCN 1154 was well tolerated with no treatment-related severe or serious adverse events and no discontinuations.
2. Post Hoc Efficacy Analysis
A post hoc cohort of 54 participants with a history of psychiatric conditions showed placebo-adjusted HAM-D17 score improvements of −7.2 (hour 12, P<0.001), −5.0 (hour 36, P<0.05), −6.1 (hour 60, P<0.01) and sustained −5.3 reduction by day 30 (P<0.05).
3. Next Steps and Strategic Options
Lipocine has applied for breakthrough therapy and fast track designations for LPCN 1154 in postpartum depression. The company plans to preserve capital and engage with investors, regulators and advisors to explore validation studies, partnerships, strategic transactions or alternative development paths.